Most recently, the incorporation of CD38-targeting antibodies into both first-line and relapse regimens has substantially improved the progression-free survival (PFS) and overall survival (OS) of both newly diagnosed and relapsed/refractory (R/R) MM patients [7,8,9,10,11]. The gene discussed is CD38; the disease is Miyoshi myopathy.